[{"id":"0af4f6ed-3aa2-4b1d-8872-fccfa3bf15e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03607188","created_at":"2021-01-18T17:43:59.726Z","updated_at":"2024-07-02T16:35:16.280Z","phase":"Phase 1","brief_title":"Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer","source_id_and_acronym":"NCT03607188","lead_sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • alkotinib (ZG0418)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 10/18/2018","start_date":" 10/18/2018","primary_txt":" Primary completion: 10/17/2022","primary_completion_date":" 10/17/2022","study_txt":" Completion: 10/17/2022","study_completion_date":" 10/17/2022","last_update_posted":"2024-03-06"}]